Sparoxomycin A1
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Category | Antibiotics |
Catalog number | BBF-02922 |
CAS | 174390-01-3 |
Molecular Weight | 377.44 |
Molecular Formula | C13H19N3O6S2 |
Online Inquiry
Capabilities & Facilities
Fermentation Lab
4 R&D and scale-up labs
2 Preparative purification labs
Fermentation Plant
Semi pilot, pilot and industrial plant 4 Manufacturing sites 7 Production lines at pilot scale 100+ Reactors of 30-4000 L; 170+ reactors of 20 KL-30 KL; 24+ reactors of >100 KL 2 Hydrogenation reactors (200 L, 4Mpa and 1000L, 4Mpa)
Product Description
It is produced by the strain of Str. sparsogenes SN 2325. It is a novel mammalian cell proliferation effector that converts the transformed phenotype of Rous sarcoma virus-infected NRK cells to a normal phenotype.
- Specification
- Properties
- Reference Reading
- Price Product List
Synonyms | 2-Propenamide, N-[(1S)-1-(hydroxymethyl)-2-[[S(R)]-[[[S(S)]-methylsulfinyl]methyl]sulfinyl]-ethyl]-3-(1,2,3,4-tetrahydro-6-methyl-2,4-dioxo-5-pyrimidinyl)-, (2E)- |
IUPAC Name | (E)-N-[(2S)-1-hydroxy-3-[(R)-[(S)-methylsulfinyl]methylsulfinyl]propan-2-yl]-3-(6-methyl-2,4-dioxo-1H-pyrimidin-5-yl)prop-2-enamide |
Canonical SMILES | CC1=C(C(=O)NC(=O)N1)C=CC(=O)NC(CO)CS(=O)CS(=O)C |
InChI | InChI=1S/C13H19N3O6S2/c1-8-10(12(19)16-13(20)14-8)3-4-11(18)15-9(5-17)6-24(22)7-23(2)21/h3-4,9,17H,5-7H2,1-2H3,(H,15,18)(H2,14,16,19,20)/b4-3+/t9-,23-,24+/m0/s1 |
InChI Key | ZIMCIWWBWLSQCN-HCGIDLGCSA-N |
Appearance | Colorless Powder |
Melting Point | 169-173°C (dec.) |
Solubility | Soluble in Methanol |
BBF-05818 | Docosahexaenoic acid | Inquiry |
BBF-03755 | Actinomycin D | Inquiry |
BBF-04624 | Sulbactam Sodium | Inquiry |
BBF-01825 | Loganin | Inquiry |
BBF-00586 | Brefeldin A | Inquiry |
BBF-05843 | Bacitracin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
